AI in Medicine News — 2026-10-07 (Wed) Evening News

Overview

- What moved the most was regulation. The UK government has accepted all 44 recommendations of the National Commission on AI Healthcare Regulation. - On the operational side, the relationship between AI and medical costs was a hot topic of discussion, and there were reports on various types of AI in diagnosis and imaging. - In drug discovery, there were announcements and funding for platforms for siRNA.

Diagnosis/Image

- AI that uses ultrasound to classify parotid gland tumors was reported to have "high accuracy." There are no numbers in the headlines, and the level of evidence is unclear. - AI model that predicts bone scintigraphy results before imaging. The headline states that accuracy may decrease over time. - Deep learning that identifies four similar inflammatory diseases from skin biopsy images. The numerical value and verification stage are unknown. - Novel biomarkers and AI aimed at reducing unnecessary prostate biopsies. It is still in the "targeting" stage and no results have been shown. - It is reported that there is a lack of public evidence regarding AI pathology testing tools, and that doctors do not understand their performance (ThePrint). - It was reported that hospital directors in Hong Kong and Shenzhen discussed the introduction of AI, and CARES 4.0 Agent was announced.

Clinical decision support

- A new AI tool that detects heart diseases that are often underdiagnosed (details not in the headline). Performance values and verification stage are unknown. - An explanatory article about the trend in remote patient monitoring from alert-based to autonomous agent-based AI.

Generation AI and medical documents/medical records

No applicable information

Hospital management/medical provision system

- Blue Cross report found that AI will drive up healthcare costs. Hospitals, on the other hand, have refuted claims that AI is driving up costs. The content of the basis for both is unclear from the headline. - Vitalize raises $31 million in Series A to expand its AI medical operations platform.

Drug discovery/clinical trials

- XtalPi announced Kodexia, an AI platform that accelerates siRNA drug discovery. The stage is based on drug discovery, and the clinical stage of specific candidates is not indicated. - Qiagen has expanded its AI biological information analysis for research and drug discovery. The target drug and the phase of the trial are not listed in the heading. - Article discussing the construction of intellectual property centered on targets, molecules, and drugs in AI drug discovery (Mondaq).

Medical device approval/regulation

- UK: The government has accepted all 44 recommendations of the national committee (acceptance of policy, not approval/designation). According to multiple reports, the plan would replace one-time approvals for medical AI with continuous monitoring throughout its lifecycle. There is no item name listed. - GE HealthCare appoints global chief AI officer (HR, not regulatory).

Safety/Error/Bias

- It was reported that the US state of Utah has signed an agreement to allow AI to support prescription drug renewal (refills). A new pillar has been added to the "pro-human AI" measures in the healthcare field, and it is reported that this is a move to expand the scope of AI utilization. Safety data is not in the headline. - The UK's acceptance of the recommendation emphasizes continuous monitoring from the perspective of ensuring safety. - As mentioned in 2. above, the lack of evidence for AI pathology tools was pointed out.

Research results (major journals)

No relevant information (The published article cannot be confirmed to be published in a major journal. The original journal of the Bioengineer.org article is unknown). Note that "Generative AI Alters the Battlefield in Mali" is not covered as it has nothing to do with medicine.

Japanese movements

- Osaka Keisatsu Hospital has started implementing the core AI system "Apollo AI." A smart hospital initiative that promotes the use of iPhone, generated AI, and in-hospital data. There are no numerical values for the effect. - Survey report: Even if the test results show "no abnormalities," more than half of them are worried about oversights. Approximately 80% of facilities that introduced AI Double Check are said to have felt a sense of security. This is a psychological investigation, not a demonstration of diagnostic accuracy. - The government is supporting the development of human resources who utilize AI and digital technology in medical and nursing care fields (Asahi Shimbun). - HRBrain's new organizational diagnostic survey feature is not covered as it has nothing to do with medical care.

Remarks from VIPs

The list of important people to be tracked is empty. There is no mention of the statement in the headline, and the Asahi Shimbun article mentions Prime Minister Sanae Takaichi's name, but the content of the statement cannot be confirmed from the headline.